EM-221
/ Eumentis Therapeutics, Mochida
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 30, 2025
EuMentis Therapeutics Receives U.S. FDA Clearance of IND Application for EM-221, a Novel PDE10A Inhibitor for Schizophrenia
(PRNewswire)
- "EuMentis Therapeutics...announced that the U.S. Food and Drug Administration (FDA) has authorized its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial of EM–221, the company's investigational phosphodiesterase 10A (PDE10A) inhibitor, in patients with schizophrenia....Company expects to initiate Phase 2 study in 2H 2025."
IND • New P2 trial • Schizophrenia
1 to 1
Of
1
Go to page
1